PARP1 and pulmonary fibrosis: Since intratracheal bleomycin administration is a well‐characterized and widely accepted model for lung fibrosis 36, 49, 50, we suggest that agents able to inhibit PARP could represent a new valuable therapeutic strategy for the treatment of this devastating disorder.